Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

Konskie,,Poland,-,February,24,,2024:,Sarepta,Therapeutics,Company,Logo

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and Roche Holdings AG (OTC:RHHBY) are collaborating to develop and commercialize gene therapy.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.